Are we ready for long-acting HIV treatment for adolescents?

Lancet HIV. 2024 Apr;11(4):e200-e201. doi: 10.1016/S2352-3018(24)00039-0.

Author

Natella Rakhmanina¹

Affiliation

¹ Division of Infectious Diseases, Childrens' National Hospital, Washington, DC, USA; The George Washington University, School of Medicine and Health Sciences, Washington, DC, USA; The Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, USA. Electronic address: nrakhman@childrensnational.org.

PMID: 38538156
DOI: 10.1016/S2352-3018(24)00039-0

No abstract available

MeSH terms

Adolescent
Anti-HIV Agents* / therapeutic use
HIV Infections* / drug therapy
Humans
Rilpivirine / therapeutic use

Substances

Rilpivirine
Anti-HIV Agents

Grants and funding

P30 AI117970/AI/NIAID NIH HHS/United States